Muscle Invasive Bladder Cancer With Chronic Kidney Disease: A Case Report
Abstract
Background: Bladder cancer ranks as the second most prevalent urinary tract cancer globally, following prostate cancer, accompanied by a significant mortality rate, and cause several complications, for example weight loss, urinary tract infections, metastases to other organs, and can cause chronic kidney failure due to obstruction of urine flow Objective: This case presented the challenging progression of muscle invasive bladder cancer with chronic kidney disease complications and refuse therapies as a clinical lesson for case management. Case Presentation: This case reports the clinical course of a 78 year old man who presented to our hospital's urology clinic presenting with symptoms of hematuria, along with urinary dripping and discomfort. Result: The patient was diagnosed with muscle invasive bladder carcinoma, with a complication of chronic kidney disease, and refused therapies. Conclusion: Controlling bladder cancer that has invaded to the muscular layer and chronic kidney disease was difficult and give poor prognosis linked to their age, type of bladder cancer, and refusal to undergo therapies.
Keywords
Full Text:
PDFReferences
Al Jameil, N. (2019). Assessment of Blood Urea Nitrogen (BUN) and Creatinine as Biochemical Markers in Chronic Kidney Disease and End Stage Renal Disease Patients Undergoing Hemodialysis. https://doi.org/10.36348/sjm.2019.v04i02.004
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic kidney disease diagnosis and management: a review. Jama, 322(13), 1294–1304.
Colemeadow, J., Hashemzehi, T., & Batura, D. (2018). Trial without catheter. British Journal of Hospital Medicine, 79(3), C42–C44. https://doi.org//10.1001/jama.2019.14745
Dobruch, J., & Oszczudłowski, M. (2021). Bladder cancer: current challenges and future directions. Medicina, 57(8), 749. https://doi.org/10.3390/medicina57080749
Erlich, A., & Zlotta, A. R. (2016). Treatment of bladder cancer in the elderly. Investigative and Clinical Urology, 57(Suppl 1), S26–S35. https://doi.org/10.4111/icu.2016.57.S1.S26
Fujita, N., Hatakeyama, S., Momota, M., Tobisawa, Y., Yoneyama, T., Yamamoto, H., Imai, A., Ito, H., Yoneyama, T., Hashimoto, Y., Yoshikawa, K., & Ohyama, C. (2020). Preoperative chronic kidney disease predicts poor prognosis in patients with primary non–muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. Urologic Oncology: Seminars and Original Investigations, 38(8), 684.e1-684.e8.
https://doi.org/https://doi.org/10.1016/j.urolonc.2020.02.001
Garg, G., Bansal, N., Singh, M., & Sankhwar, S. N. (2019). Role of percutaneous nephrostomy in bladder carcinoma with obstructive uropathy: a story revisited. Indian Journal of Palliative Care, 25(1), 53. https://doi.org/10.4103/IJPC.IJPC_102_18
Gharibvand, M. M., Kazemi, M., Motamedfar, A., Sametzadeh, M., & Sahraeizadeh, A. (2017). The role of ultrasound in diagnosis and evaluation of bladder tumors. Journal of Family Medicine and Primary Care, 6(4), 840–843. https://doi.org/10.4103/jfmpc.jfmpc_186_17
Ilgi Sr, M., Bayar, G., Abdullayev, E., Cakmak, S., Acinikli, H., Kirecci, S. L., & Horasanli, K. (2020). Rare causes of hydronephrosis in adults and diagnosis algorithm: Analysis of 100 cases during 15 years. Cureus, 12(5). https://doi.org/10.7759/cureus.8226
Kim, L. H. C., & Patel, M. I. (2020). Transurethral resection of bladder tumour (TURBT). Translational Andrology and Urology, 9(6), 3056. https://doi.org/10.21037/tau.2019.09.38
Leslie, S., Soon-Sutton, T., & Aeddula, N. (2024). Bladder cancer. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK536923/
Lin, W., Pan, X., Zhang, C., Ye, B., & Song, J. (2023). Impact of age at diagnosis of bladder cancer on survival: a surveillance, epidemiology, and end results-based study 2004-2015. Cancer Control, 30, 10732748231152322. https://doi.org/10.1177/10732748231152322
Murdeshwar, H. N., & Anjum, F. (2020). Hemodialysis. StatPearls. https://pubmed.ncbi.nlm.nih.gov/33085443/
Ogawa, K., Shimizu, Y., Uketa, S., Utsunomiya, N., & Kanamaru, S. (2020). Prognosis of patients with muscle invasive bladder cancer who are intolerable to receive any anti-cancer treatment. Cancer Treatment and Research Communications, 24, 100195.
https://doi.org/https://doi.org/10.1016/j.ctarc.2020.100195
Onen, A. (2020). Grading of hydronephrosis: an ongoing challenge. Frontiers in Pediatrics, 8, 538943. https://doi.org/10.3389/fped.2020.00458
Paul, J. (2023). Hydronephrosis and its impact on kidney function. Pediatr Urol Case Rep, 10(4), 309–310. https://doi.org/10.14534/j-pucr.20222675603
Perix, V. K., Suryanti, S., & Sihombing, A. T. (2017). Five Years Facts of Bladder Cancer at West Java’s Top Referral Hospital, in Indonesia. Althea Medical Journal, 4(1), 94–99. https://doi.org/10.15850/amj.v4n1.1028
Pinto, I. G. (2017). Systemic therapy in bladder cancer. Indian Journal of Urology, 33(2), 118–126. https://doi.org/10.4103/iju.IJU_294_16
Seki, M., Nakayama, M., Sakoh, T., Yoshitomi, R., Fukui, A., Katafuchi, E., Tsuda, S., Nakano, T., Tsuruya, K., & Kitazono, T. (2019). Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3–5 chronic kidney disease: a prospective observational study. BMC Nephrology, 20(1), 115. https://doi.org/10.1186/s12882-019-1306-1
Sengsuk, J., Tangvarasittichai, O., & Tangvarasittichai, S. (2018). Serum Uric Acid to Creatinine ratio as a marker of Estimated Glomerular Filtration Rate in type 2 diabetes patients. Madridge J Diabetes, 2(1), 36–41. https://doi.org/10.18689/mjd-1000107
Strother, M., Barlotta, R., Uzzo, R., Bloom, E., Jazayeri, S. B., Bigalli, A. C., Schober, J., Lee, J., Bernstein, A., Ginsburg, K., Handorf, E., Chen, D. Y. T., Correa, A., Greenberg, R., Smaldone, M., Viterbo, R., & Kutikov, A. (2024). Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment. Urologic Oncology: Seminars and Original Investigations, 42(4), 117.e1-117.e10.
https://doi.org/https://doi.org/10.1016/j.urolonc.2023.12.007
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/https://doi.org/10.3322/caac.21660
Tanariyakul, M., Saowapa, S., Polpichai, N., Wannaphut, C., Yingchoncharoen, P., Thongpiya, J., Siladech, P., Olavarria Bernal, D. A., Chaisrimaneepan, N., & Dejthevaporn, T. S. (2024). Kidney outcomes in patients with bladder cancer: Insights from real-world data—A National Inpatient Sample (NIS) study, 2020. American Society of Clinical Oncology.
https://doi.org/10.1200/JCO.2024.42.16_suppl.e16622
Tayfur, M., & Balcı, M. (2022). Hydronephrosis due to bladder carcinoma. Journal of Surgery and Medicine, 6(1), 80–81. https://doi.org/10.28982/josam.885593
van der Heijden, A. G., Bruins, H. M., Carrion, A., Cathomas, R., Compérat, E., Dimitropoulos, K., Efstathiou, J. A., Fietkau, R., Kailavasan, M., Lorch, A., Martini, A., Mertens, L. S., Meijer, R. P., Mariappan, P., Milowsky, M. I., Neuzillet, Y., Panebianco, V., Sæbjørnsen, S., Smith, E. J., … Rink, M. (2025). European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. European Urology. https://doi.org/https://doi.org/10.1016/j.eururo.2025.02.019
Yan, M.-T., Chao, C.-T., & Lin, S.-H. (2021). Chronic kidney disease: strategies to retard progression. International Journal of Molecular Sciences, 22(18), 10084. https://doi.org/10.3390/ijms221810084
DOI: http://dx.doi.org/10.30742/jikw.v14i2.4273
Refbacks
- There are currently no refbacks.
Copyright (c) 2025 Hendro Kusdianto, Muflikhah Ramadhani, Suryo Prasetyo Triwibowo, Novalia Chumaladewi Guntarno

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Jurnal Ilmiah Kedokteran Wijaya Kusuma is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License